World's Best Scientists 2026 revealed!
Franco Franceschini

Franco Franceschini

D-Index & Metrics

Immunology

D-Index
56
Citations
11971
World Ranking
3715
National Ranking
152

Franco Franceschini publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Franco Franceschini sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 406 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Franco Franceschini D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Franco Franceschini sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 56 D-Index — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Franco Franceschini is affiliated with the University of Brescia in Italy. Their research primarily focuses on medicine, with significant contributions to rheumatology, pathology and forensic medicine, immunology, pulmonary and respiratory medicine, and infectious diseases.

Their work covers several main research topics including systemic lupus erythematosus research, systemic sclerosis and related diseases, inflammatory myopathies and dermatomyositis, vasculitis and related conditions, monoclonal and polyclonal antibodies research, pregnancy and medication impact, and SARS-CoV-2 and COVID-19 research.

Franceschini has contributed to several recent publications, including:

  • Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy (2020, Autoimmunity Reviews)
  • Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system (2020, Blood Reviews)
  • Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome (2020, Frontiers in Immunology)
  • Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome (2020, Annals of the Rheumatic Diseases)
  • COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study (2020, The Lancet Rheumatology)

Their frequent co-authors include:

  • Micaela Fredi
  • Laura Andréoli
  • Anǵela Tincani
  • Ilaria Cavazzana
  • Maria Grazia Lazzaroni

The main venues where Franceschini publishes work include:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • Clinical and Experimental Rheumatology
  • Poster presentations
  • Frontiers in Medicine

Best Publications

  • Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.

    Paola Toniati;Simone Piva;Marco Cattalini;Emirena Garrafa

  • Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women

    Antonio Brucato;Micol Frassi;Franco Franceschini;Rolando Cimaz

  • Anti-Ro/SSA and La/SSB antibodies

    F. Franceschini;I. Cavazzana

  • Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients

    Claudio Vitali;Gianluigi Palombi;Chiara Baldini;Maurizio Benucci

  • Novel aspects of Sjögren’s syndrome in 2012

    Angela Tincani;Laura Andreoli;Ilaria Cavazzana;Andrea Doria

  • Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

    Lorenzo Cavagna;Ernesto Trallero-Araguás;Federica Meloni;Ilaria Cavazzana

  • Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study

    A Brucato;A Doria;M Frassi;G Castellino

  • Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study.

    Lorenzo Cavagna;Laura Nuño;Carlo Alberto Scirè;Marcello Govoni

  • Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system.

    Maria Grazia Lazzaroni;Silvia Piantoni;Stefania Masneri;Emirena Michela Garrafa

  • Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.

    Maria Orietta Borghi;Asmaa Beltagy;Emirena Garrafa;Daniele Curreli

  • Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms.

    Elisabetta Danieli;Paolo Airò;Lorenzo Bettoni;Massimo Cinquini

  • Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera

    Ilaria Cavazzana;Micaela Fredi;Angela Ceribelli;Cristina Mordenti

  • Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis

    Angela Ceribelli;Micaela Fredi;Mara Taraborelli;Ilaria Cavazzana

  • Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

    Alessandra Bettiol;Maria Letizia Urban;Lorenzo Dagna;Vincent Cottin

  • Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients.

    R Gerli;Laura Caponi;A Tincani;R Scorza

  • Myositis autoantibodies and clinical phenotypes.

    Anna Ghirardello;Elisabetta Borella;Marianna Beggio;Franco Franceschini

  • Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus.

    Patrick Gordon;Munther A Khamashta;Eric Rosenthal;John M Simpson

  • Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.

    Luca Iaccarino;Silvano Bettio;Rossella Reggia;Margherita Zen

  • COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study.

    Micaela Fredi;Ilaria Cavazzana;Liala Moschetti;Laura Andreoli

  • Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study

    Lucile Musset;Yves Allenbach;Olivier Benveniste;Olivier Boyer

  • Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.

    Francesco Perrone;Maria Carmela Piccirillo;Paolo Antonio Ascierto;Carlo Salvarani

  • Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies

    Paolo Airo;Angela Ceribelli;Ilaria Cavazzana;Mara Taraborelli

Frequent Co-Authors

Ilaria Cavazzana
Ilaria Cavazzana University of Brescia
Angela Tincani
Angela Tincani University of Brescia
Paolo Airò
Paolo Airò University of Brescia
Carlomaurizio Montecucco
Carlomaurizio Montecucco University of Pavia
Andrea Doria
Andrea Doria University of Padua
Roberto Caporali
Roberto Caporali University of Milan
Marta Mosca
Marta Mosca University of Pisa
Minoru Satoh
Minoru Satoh RMIT University
Carlo Selmi
Carlo Selmi Humanitas University
Fabrizio Conti
Fabrizio Conti Sapienza University of Rome

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology, exploring related degrees in healthcare can open diverse career pathways. Many students transition into nursing or advanced practice roles where immunology knowledge is highly valued.

One popular route is enrolling in an fnp to acnp bridge program online, which allows Family Nurse Practitioners to specialize further in acute care settings. This bridge enhances clinical skills and deepens understanding of immune-related conditions.

Similarly, accelerated nursing programs, such as an accelerated fnp program, offer a fast track for individuals holding a bachelor’s degree in another field to become Nurse Practitioners. These programs attract many aspiring healthcare professionals.

For those without prior nursing experience, enrolling in online rn programs for non nurses provides foundational education that can later lead to advanced study in immunology-related specialties.

Finally, to start their nursing career quickly, many students seek out accelerated nursing programs near me. These programs offer an efficient path to obtain a Bachelor of Science in Nursing (BSN) and pave the way for immunology-focused roles in healthcare settings.

Best Scientists Citing Franco Franceschini

Trending Scientists

Recently Published Articles